Loading...

Sirnaomics Ltd.

2257.HK•HKSE
Healthcare
Biotechnology
HK$5.81
HK$0.21(3.75%)

Sirnaomics Ltd. (2257.HK) Stock Overview

Explore Sirnaomics Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.9/100

Key Financials

Market Cap611M
P/E Ratio-1.14
EPS (TTM)$-5.18
ROE71.56%
Fundamental Analysis

AI Price Forecasts

1 Week$4.06
1 Month$1.53
3 Months$1.24
1 Year Target$1.54

2257.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Sirnaomics Ltd. (2257.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 66.81, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.54.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.14 and a market capitalization of 611M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

66.81RSI (14)
0.54MACD
59.69ADX
Stats data is not available for 2257.HKStats details for 2257.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 2257.HKAnalyst Recommendations details for 2257.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat sculpting. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP902 to treat breast cancer; STP702 for the treatment of influenza; STP908 to treat COVID-19; RIM730 COVID-19 vaccine; STP909 for the treatment of HPV/cervical cancer; and STP122G for thrombotic disorders. In addition, the company is developing STP125G to treat hypertriglyceridemia; STP144G for the treatment of complement-mediated diseases; STP133G for cardiometabolic; and STP155G for the treatment hepatitis B virus. Sirnaomics Ltd. was founded in 2007 and is headquartered in Gaithersburg, Maryland.

CEO

Hung Fai Poon

Employees

69

Headquarters

401 Professional Drive, Gaithersburg, MD

Founded

2021

Frequently Asked Questions

;